Neogap Therapeutics, a leading biotech company specializing in personalized cancer immunotherapy, has announced the appointment of Dr. Hanjing Xie as its new Chief Medical Officer (CMO). Dr. Xie will be responsible for overseeing the clinical development programs and pipeline of Neogap and providing medical oversight for the company’s first-in-human study.
Who is Dr. Hanjing Xie?
Dr. Hanjing Xie is an experienced associate professor and senior consultant in oncology with over 25 years of experience in the pharmaceutical industry and university hospitals. She holds a Ph.D. in clinical pharmacology and has board certifications in clinical oncology, internal medicine, and hematology. Dr. Xie has worked for companies such as Idogen, Oncopeptides, and Bayer, as well as for university hospitals and institutes such as the Karolinska University Hospital, the Karolinska Institute, and St. Göran’s hospital.
What are the responsibilities of Dr. Hanjing Xie as CMO of Neogap Therapeutics?
As the new CMO of Neogap Therapeutics, Dr. Hanjing Xie will oversee the clinical development programs and pipeline of the company, which includes the recently approved phase I/IIa clinical trial with its advanced cell therapy pTTL against colorectal cancer. The trial is expected to begin in the first half of 2023. Dr. Xie will also provide medical oversight for the company’s first-in-human study.
What does this appointment mean for Neogap Therapeutics?
According to Samuel Svensson, CEO of Neogap Therapeutics, “We are thrilled to welcome Dr. Hanjing Xie as our new Chief Medical Officer. With extensive experience in research, clinical development, and patient care, Dr. Xie brings a wealth of expertise to Neogap. Her diverse background in the pharmaceutical industry and academia, along with specialized training in clinical oncology and hematology, make her highly qualified to lead our cell therapy trial.”
Dr. Xie expressed her excitement about joining Neogap and contributing to the company’s efforts to enhance tumor-specific immune responses and increase survival rates for cancer patients.
The appointment of Dr. Hanjing Xie as the new CMO of Neogap Therapeutics is a significant development for the company’s personalized cancer immunotherapy development. With her extensive experience in the pharmaceutical industry and academia, Dr. Xie brings a wealth of expertise to Neogap and is highly qualified to lead the company’s cell therapy trial. This appointment is expected to drive Neogap’s clinical development programs and pipeline, as well as enhance tumor-specific immune responses and increase survival rates for cancer patients.
David Brobst is a journalist who reports on news and current events. He has extensive experience covering a wide range of topics, including politics, business, and technology. Brobst is known for his thorough research and in-depth analysis of complex issues. He is a skilled interviewer and storyteller, and his work is highly respected in the industry.
Brobst has won several awards for his reporting and is considered a leading authority on the subjects he covers. He is a frequent guest on television and radio programs, and his work has been published in major newspapers and magazines. Brobst is dedicated to providing accurate, unbiased, and insightful coverage of the events shaping our world.
Email: [email protected]